This page is free to read, and it stops after 4 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the company page behind every filing, is part of the subscription. So are this filer’s key figures — how many filings and open-market buys they reported, and over which period — the price beside each line, and the measured buy-following figure where there is one. What that costs is on the pricing page.
Filings
4On an award the register reports a price of 0: nothing was paid, and the Quantity column shows the size.
| Company | Transaction | Reported |
|---|---|---|
| TME Pharma N.V.Managing Director / Chief Executive Officer | Open-market buy€13,500quantity 135,000 | Sep 30, 2025 |
| TME Pharma N.V.Managing Director / Chief Executive Officer | Open-market buy€6,500quantity 65,000 | Sep 29, 2025 |
| TME Pharma N.V.Managing Director / Chief Executive Officer | Open-market buy€3,000quantity 30,000 | Sep 26, 2025 |
| TME Pharma N.V.Managing Director / Chief Executive Officer | Open-market buy€9,500quantity 95,000 | Sep 25, 2025 |